Janssen Pharmaceuticals Receives FDA Approval for Diabetes Combination Product
Janssen Pharmaceuticals, Inc. reports that US Food and Drug Administration (FDA) has approved Invokamet, a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with Type 2 diabetes.
The combination therapy of Invokamet provides the clinical attributes of Invokana (canagliflozin), a sodium glucose co-transporter 2 (SGLT2) inhibitor for treating Type 2 diabetes. Invokamet will be available in tablets containing canagliflozin 50 mg or 150 mg, and metformin 500 mg or 1000 mg. The recommended dosing is twice daily. The FDA approved Invokana as a single agent to treat Type 2 diabetes in March 2013
Source: Johnson & Johnson
